Uncategorized

[Nature] In humans and mice and across mutations in Jak2, Tet2, Trp53 and Dnmt3a, researchers demonstrated mutation-dependent responses to sleep and exercise in clonal haematopoiesis and showed that mutant cells are uniquely sensitive to lifestyle.

[Blood] Scientists identified METTL1 as a key regulator of leukemia stem cell self-renewal and homing within bone marrow microenvironment through catalyzing m⁷G formation on a specific tRNA, tRNA^Phe_GAA, thereby promoting leukemogenesis.

[Cell Death & Disease] Researchers found that multiple lipid metabolism processes are aberrantly activated in Ara-C resistant AML cells, accompanied by upregulation of JAK-STAT3 signaling and key lipid metabolic regulators, notably SREBP1 and CPT2.

[Cancer Cell International] Investigators elucidated the BRD4-PIM1 axis as a critical driver of acute megakaryoblastic leukemia pathogenesis, wherein BRD4 maintains high PIM1 expression through SE-mediated transcriptional regulation.

[iScience] Researchers elucidated the expression profile of aldehyde dehydrogenase 3 family member A2 (ALDH3A2) in real-world AML patients and its impact on the efficacy of chemotherapy and explored the effect of inhibiting ALDH3A2 activity or expression on enhancing the sensitivity to chemotherapy.

[Scientific Reports] Scientists aimed to systematically investigate the role and potential mechanisms of PGAM5 in AML. Bioinformatics analysis revealed that PGAM5 expression was significantly upregulated in AML patients compared with healthy controls,

[Biochemical Pharmacology] Scientists summarize the biological roles of p53, examine how TP53 gene alterations drive therapeutic resistance in myeloid neoplasms, and compare contemporary classification frameworks,

[Mechanisms of Ageing and Development] The authors contextualize CD34⁺ cell biology within aging mechanisms, offering a cohesive view on illness onset and highlighting prospects for early intervention in older populations.

[Columbia University] Dr. Michel Sadelain of Columbia University has been awarded a Tang Prize in Biopharmaceutical Science “for the discovery and development of tumor-infiltrating lymphocyte and chimeric antigen receptor T cell therapies, which have revolutionized treatment for blood cancers and solid tumors.”

[CARsgen Therapeutics] CARsgen Therapeutics announced that the New Drug Application of satricabtagene autoleucel, the autologous humanized Claudin18.2 CAR T-cell therapy product, was approved for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma who have failed at least two prior lines of therapy.

[Nature Immunology] Researchers showed that costimulatory domains control memory fate acquisition through asymmetric cell division. CD28 CAR T cells have higher CAR surface expression and enhanced surface proteome asymmetry after the first division, yet they show muted transcriptional and metabolic divergence between daughter cells.

[Blood Cancer Journal] The authors evaluated 63 acute myeloid leukemia (AML)-associated antigens for which CAR constructs have been reported. They provide a prioritized antigen landscape and a framework to guide the rational design of next-generation CARs for this challenging malignancy.